Leap Therapeutics Reports Second Quarter 2020 Financial Results
CAMBRIDGE, Mass., Aug. 13, 2020 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2020.
Leap Second Quarter Highlights:
- Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock
- Presented updated data for DKN-01 monotherapy that showed a complete response and parti…
